Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ADAMTS5 | Q9UNA0 | 4/20 | 0.45 |
| ▸ | MMP13 | P45452 | 3/20 | 0.45 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP14 | P50281 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | ADAMTS1 | Q9UHI8 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1827202 | 0.89 | KDM4E (0.54) | KDM4EHSD17B10KMT2AF10ABL1 | |
| SCHEMBL1825586 | 0.89 | NR4A2 (0.55) | KDM4EHSD17B10KMT2APOLBMEN1 | |
| SCHEMBL1824677 | 0.88 | KDM4E (0.52) | KDM4EHSD17B10KMT2APOLBMEN1 | |
| SCHEMBL1826208 | 0.88 | KDM4E (0.52) | KDM4EHSD17B10KMT2APOLBMEN1 | |
| SCHEMBL1826609 | 0.87 | KDM4E (0.49) | KDM4EHSD17B10KMT2AMEN1F10 | |
| SCHEMBL1826748 | 0.86 | KDM4E (0.50) | KDM4EHSD17B10F10ABL1CYP2C19 | |
| SCHEMBL1823741 | 0.85 | KMT2A (0.58) | KDM4EHSD17B10KMT2AF10NR4A2 | |
| SCHEMBL1823452 | 0.85 | ADAMTS4 (0.48) | KDM4EADAMTS5MMP13ADAMTS4MMP2 | |
| SCHEMBL4446018 | 0.83 | KDR (0.42) | KDM4EHSD17B10KMT2AMEN1F10 | |
| SCHEMBL1823309 | 0.81 | KDM4E (0.52) | KDM4EHSD17B10KMT2AMEN1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461205-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | CHELSEA THERAPEUTICS, INC. | 2012-11-08 | — | — | US | claimed |
| US-8263658-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2012-09-11 | — | — | US | claimed |
| EP-2118051-B1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS INC (US) | 2011-05-04 | — | — | EP | claimed |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | Chelsea Therapeutics, Inc | 2010-02-04 | — | — | US | claimed |
| US-8461205-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | CHELSEA THERAPEUTICS, INC. | 2012-11-08 | — | — | US | disclosed |
| US-8263658-B2 | Anthranilic acid derivatives | CHELSEA THERAPEUTICS, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2118051-B1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS INC (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | Chelsea Therapeutics, Inc | 2010-02-04 | — | — | US | disclosed |
| EP-2118051-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | Chelsea Therapeutics, Inc. (US) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008097180-A1 | NEW COMPOUNDS, METHODS FOR THEIR PREPARATION AND USE THEREOF | CHELSEA THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283326-A1 | ANTHRANILIC ACID DERIVATIVES | ACOX3, BCL3, AOC3 | KDM4E 4207/4885HSD17B10 1370/4885ADAMTS5 4825/4885 |
| US-20100029767-A1 | ANTHRANILIC ACID DERIVATIVES | ACOX3, BCL3, AOC3 | KDM4E 4172/4885HSD17B10 1349/4885ADAMTS5 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.